Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate…
Systemic Lupus Erythematosus (SLE), also known as lupus, is a chronic,inflammatory, autoimmune disease affecting 5 million people worldwidewith 70%-90% of these cases appearing in females
ImmuPharma has completed a fundraise totalling £10 million (14.03million) before expenses by placing 6,944,445 new ordinary shares of 10p each…
ImmuPharma said Friday that 200 patients were recruited and dosed in its Phase III trial of Lupus drug Lupuzor. Furthermore, all 200 patients have passed the 3 months stage, with over 90% of patients (184) have passed 6 months.
Neovacs has completed patient enrollment for for its phase IIb clinical study, IFN-K-002, evaluating IFNalpha Kinoid for the treatment of lupus.
Neovacs has signed with BioSense Global a commercial license option agreement for its IFNalpha Kinoid vaccine to treat lupus and dermatomyositis in China, worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.
ImmuPharma has provided details of patient recruitment into its pivotal 52-week Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus.
ImmuPharma has completed patients recruitment regarding pivotal Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough…
The U.S. Food and Drug Administration (FDA) has granted “Fast Track” status to French biopharmaceutical company Neovacs’s IFNalpha Kinoid in…
Neovacs, a player in active immunotherapy for the treatment of autoimmune diseases, has enroled the first U.S. patient in its international Phase IIb clinical study of IFNalpha Kinoid in lupus.